Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

*Age Limits - 18 years or older outside of the US, 22 years or older within the US.

Inclusion Criteria:

1. Histologically confirmed diagnosis of GBM according to WHO classification criteria.

2. Age ≥ 22 years in US and Age ≥ 18 years in Ex-US

3. Recovered from maximal debulking surgery, if applicable (gross total resection,partial resection, and biopsy-only patients are all acceptable)

4. Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200mg/m2 daily x 5 d, q28 days)

5. Karnofsky performance status ≥ 70

6. Life expectancy ≥ least 3 months

7. Participants of childbearing age must use highly effective contraception. Aneffective method of birth control is defined as one that results in a failure rateof less than 1% per year when used consistently and correctly. The Investigator mustapprove the selected method, and may consult with a gynecologist as needed.

8. All patients must understand and voluntarily sign an informed consent document priorto any study related assessments/procedures being conducted.

9. Stable or decreasing dose of corticosteroids for the last 7 days prior torandomization, if applicable.

10. Concomitant RT with TMZ treatment planned to start no later than 8 weeks fromsurgery

11. Women of childbearing potential must have a negative β-HCG pregnancy test documentedwithin 14 days prior to randomization

12. Is able to have MRI with contrast of the brain

Exclusion Criteria:

1. Progressive disease (per investigator's assessment)

2. Infratentorial or leptomeningeal disease

3. Participation in another clinical treatment study during the pre-treatment and/orthe treatment phase of the study

4. Pregnancy or breast-feeding.

5. Significant co-morbidities at baseline which would preclude maintenance RT or TMZtreatment, as determined by the investigator:

6. Thrombocytopenia (platelet count < 100 x 103/μL)

7. Neutropenia (absolute neutrophil count < 1.5 x 103/μL)

8. CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)

9. Significant liver function impairment - AST or ALT > 3 times the upper limit ofnormal

10. Total bilirubin > 1.5 x upper limit of normal

11. Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)

12. History of any psychiatric condition that might impair patient's ability tounderstand or comply with the requirements of the study or to provide consent

13. Implanted pacemaker, defibrillator, deep brain stimulator, other implantedelectronic devices in the brain, or documented clinically significant arrhythmias.

14. Evidence of increased intracranial pressure (midline shift > 5mm, clinicallysignificant papilledema, vomiting and nausea or reduced level of consciousness)

15. History of hypersensitivity reaction to TMZ or a history of hypersensitivity toDTIC.

16. Additional malignancies that are progressing or required active treatment in thelast two years.

17. Admitted to an institution by administrative or court order.

18. Known allergies to medical adhesives or hydrogel

19. A skull defect (such as, missing bone with no replacement)

20. Prior radiation treatment to the brain for the treatment of GBM

21. Any serious surgical/post-operative condition that may put the participant at riskaccording to the investigator.

22. Standard TTFields exclusion criteria include

23. Active implanted medical devices

24. Bullet fragments

25. Skull defects